{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2"},{"groupId":"OG001","value":"76.0"},{"groupId":"OG002","value":"81.2"},{"groupId":"OG003","value":"83.3"},{"groupId":"OG004","value":"82.2"},{"groupId":"OG005","value":"83.9"}]}],"title":"ACR20"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2"},{"groupId":"OG001","value":"50.6"},{"groupId":"OG002","value":"58.1"},{"groupId":"OG003","value":"59.6"},{"groupId":"OG004","value":"62.5"},{"groupId":"OG005","value":"67.8"}]}],"title":"ACR50"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4"},{"groupId":"OG001","value":"27.1"},{"groupId":"OG002","value":"38.2"},{"groupId":"OG003","value":"41.9"},{"groupId":"OG004","value":"42.1"},{"groupId":"OG005","value":"45.8"}]}],"title":"ACR70"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8"},{"groupId":"OG001","value":"5.2"},{"groupId":"OG002","value":"11.3"},{"groupId":"OG003","value":"15.3"},{"groupId":"OG004","value":"16.8"},{"groupId":"OG005","value":"19.3"}]}],"title":"ACR90"}],"denoms":[{"counts":[{"groupId":"OG000","value":"522"},{"groupId":"OG001","value":"480"},{"groupId":"OG002","value":"422"},{"groupId":"OG003","value":"413"},{"groupId":"OG004","value":"387"},{"groupId":"OG005","value":"367"}],"units":"Participants"}],"description":"The American College of Rheumatology (ACR) established certain criteria to measure improvement in rheumatoid arthritis symptoms that include tender or swollen joint counts and five other criteria, including acute phase reactant, patient assessment, physician assessment, pain scale, and disability/functional questionnaire.\n\nClinical trials use the ACR Score, based on those criteria, as a standard for reporting different degrees of improvement in rheumatoid arthritis symptoms.\n\nScores on the ACR scale may be up to ACR100 because the number after \"ACR\" is the percent of improvement in tender or swollen joint counts as well as in three of the other five criteria. Clinical trials determine the percentage of participants who achieve that score - that percentage of improvement.","groups":[{"description":"Participants with scores at 24 weeks post-baseline.","id":"OG000","title":"Week 24"},{"description":"Participants with scores at 48 weeks post-baseline.","id":"OG001","title":"Week 48"},{"description":"Participants with scores at 108 weeks post-baseline.","id":"OG002","title":"Week 108"},{"description":"Participants with scores at 156 weeks post-baseline.","id":"OG003","title":"Week 156"},{"description":"Participants with scores at 204 weeks post-baseline.","id":"OG004","title":"Week 204"},{"description":"Participants with scores at 264 weeks post-baseline.","id":"OG005","title":"Week 264"}],"paramType":"NUMBER","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab, with a score at the given time point.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Participants Showing Improvement in Rheumatoid Arthritis Symptoms Over Time, Through 264 Weeks","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}